September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
July 2022 in “Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ” Lower zinc levels are linked to more severe hair loss in alopecia areata.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
September 2025 in “Journal of Dhaka Medical College” Lower vitamin D levels are linked to more severe alopecia areata.
26 citations
,
June 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Regenerative therapies show promise for treating vitiligo and alopecia areata.
6 citations
,
January 2023 in “Annals of Dermatology” The guidelines offer updated treatment recommendations for alopecia areata in Korea using topical and device-based methods.
July 2025 in “Berkala Ilmu Kesehatan Kulit dan Kelamin” Alopecia areata in children shows varied symptoms and may involve nails, needing further evaluation for other health issues.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
205 citations
,
April 2013 in “British Journal of Dermatology” Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
128 citations
,
February 2016 in “British Journal of Dermatology” Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
67 citations
,
March 2021 in “Dermatology and Therapy” Alopecia areata greatly harms quality of life, causing emotional and social issues.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
63 citations
,
May 2017 in “American Journal of Clinical Dermatology” People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.
62 citations
,
October 2016 in “Dermatologic Therapy” PRP more effective than minoxidil 5% for treating alopecia areata.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
54 citations
,
March 1987 in “Journal of The American Academy of Dermatology” 3% topical minoxidil effectively treats extensive alopecia areata with few side effects.
49 citations
,
April 2000 in “Journal of The American Academy of Dermatology” Despite progress in treatment, the exact cause of Alopecia areata is still unknown.
49 citations
,
November 1992 in “Archives of dermatology” Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
46 citations
,
May 1997 in “British journal of dermatology/British journal of dermatology, Supplement” Vitiligo is not linked to coeliac disease, but a small number of alopecia areata patients may have it, suggesting they should be tested for coeliac disease.